Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026

Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview

• Ribonucleic Acid (RNA) Therapy Clinical Trials market size has reached to $2.7 billion in 2025 • Expected to grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.7% • Growth Driver: Rising Burden Of Infectious Diseases Fueling The Growth Of The Market Due To Antimicrobial Resistance And Demand For Rapid Therapeutic Development • Market Trend: Innovative RNA-Based Antisense Oligonucleotide Trials Target Genetic Eye Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ribonucleic Acid (RNA) Therapy Clinical Trials Market?

Ribonucleic acid (RNA) therapy clinical trials are research studies designed to evaluate the safety, efficacy, and optimal use of therapies that utilize ribonucleic acid (RNA)-based molecules to treat or prevent diseases. These trials aim to develop innovative medical interventions that work by modulating gene expression, correcting genetic defects, or enabling the body to produce beneficial proteins to treat or prevent various diseases. The main types of modalities in ribonucleic acid (RNA) therapy clinical trials are ribonucleic acid (RNA) interference, antisense therapy, messenger ribonucleic acid (mRNA), oligonucleotide, non-antisense, and non-ribonucleic acid interference (RNAi). Ribonucleic acid (RNA) interference refers to a natural cellular process in which small RNA molecules inhibit gene expression or translation by neutralizing targeted messenger ribonucleic acid (RNA) molecules. These trials span multiple clinical phases, such as phase I, phase II, phase III, and phase IV, and address a wide range of therapeutic areas, including rare diseases, anti-infectives, anticancer, neurological, alimentary or metabolic, musculoskeletal, cardiovascular respiratory, sensory, and others.

What Is The Ribonucleic Acid (RNA) Therapy Clinical Trials Market Growth Forecast?

The ribonucleic acid (rna) therapy clinical trials market size is expected to see steady growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advancements in rna delivery technologies, increasing funding for rare disease and anticancer research, growing collaboration between biotech and pharma companies, rising adoption of personalized medicine approaches, expansion of global clinical trial networks. Major trends in the forecast period include increasing number of rna therapy clinical trials across therapeutic areas, growing focus on rare disease and anticancer rna therapeutics, expansion of mrna vaccine and self-amplifying rna therapy trials, adoption of crispr and rna editing-based therapy trials, integration of advanced delivery platforms and oligonucleotide conjugates.

Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Segmentation

1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi) 2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV 3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas Subsegments: 1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials 2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials 3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials 4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials 5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials 6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials

What Is The Driver Of The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?

The increasing burden of infectious diseases is expected to propel the growth of the ribonucleic acid (RNA) therapy clinical trials market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and impair health. The rise in infectious diseases is largely driven by the rise in global travel, which facilitates the rapid spread of pathogens across regions and populations. Ribonucleic acid (RNA) therapy clinical trials help combat infectious diseases by enabling the development and evaluation of targeted treatments that can quickly adapt to emerging pathogens. For instance, in April 2025, according to a report published by the Minnesota Department of Health, a US-based state agency, in 2024, the proportion of HIV cases among males aged 35 to 39 increased from 10% in 2023 to 17%. Therefore, the increasing burden of infectious diseases is driving the growth of the ribonucleic acid (RNA) therapy clinical trials industry.

Key Players In The Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market

Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.

Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Trends and Insights

Major companies operating in the ribonucleic acid (RNA) therapy clinical trials market are focusing on developing innovative solutions, such as RNA-based antisense oligonucleotide therapy clinical trials, to target specific genetic sequences, modulate gene expression, and offer highly precise treatments for genetic and rare diseases. An RNA-based antisense oligonucleotide therapy clinical trial refers to a study that investigates the use of short synthetic RNA strands to bind specific messenger RNA targets, aiming to modulate gene expression and treat genetic disorders. For instance, in December 2024, Sepul Bio, a France-based biotechnology company, initiated the LUNA Phase 2b clinical trial to evaluate ultevursen, an RNA-based antisense oligonucleotide therapy targeting mutations in exon 13 of the USH2A gene, which cause retinitis pigmentosa (RP) and Usher syndrome type 2a. This two-year, double-masked, randomized, sham-controlled study will enroll 81 adults and children aged eight and above across multiple global sites. The therapy is intended for individuals with RP or non-syndromic RP due to exon 13 mutations in USH2A, which can be confirmed by genetic testing. The LUNA trial follows promising results from earlier Phase 1/2 studies, where ultevursen showed benefits in visual acuity, retinal sensitivity, and retinal structure.

What Are Latest Mergers And Acquisitions In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market?

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma for $1 billion. Through this acquisition, Novartis aims to strengthen its neuroscience pipeline and expand its capabilities in ribonucleic acid (RNA)-based therapeutics by integrating DTx Pharma’s FALCON platform and advancing innovative small interfering ribonucleic acid (siRNA) programs for neuromuscular and neurological disorders. DTx Pharma is a US-based company that offers ribonucleic acid (RNA)-based therapeutics clinical trials for neuromuscular and neurological disorders.

Regional Insights

North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ribonucleic Acid (RNA) Therapy Clinical Trials Market?

The ribonucleic acid (RNA) therapy clinical trials market includes revenues earned by entities by providing services, such as RNA therapeutic administration, biological sample collection and analysis, long-term follow-up, genetic and molecular testing, and patient screening and enrollment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report 2026?

The ribonucleic acid (rna) therapy clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) therapy clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.